KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) vs placebo (pbo) plus gem/cis for patients (pts) with advanced biliary tract cancer (BTC)
Ueno, M. Finn, R. S. Yoo, C. Ren, Z. Furuse, J. Kelley, R. K. Chan, S. L. Edeline, J. Klumpen, H. J. Yau, T.
Ueno, M.
Finn, R. S.
Yoo, C.
Ren, Z.
Furuse, J.
Kelley, R. K.
Chan, S. L.
Edeline, J.
Klumpen, H. J.
Yau, T.
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Ueno M, Finn RS, Yoo C, Ren Z, Furuse J, Kelley RK, et al. KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) vs placebo (pbo) plus gem/cis for patients (pts) with advanced biliary tract cancer (BTC). ANNALS OF ONCOLOGY. 2024 DEC;35:S1459-S60. PubMed PMID: WOS:001401985200133. English.